Tumor-associated cells recognized by haNK cell activating receptors

Tumor-associated cells recognized by haNK cell activating receptors refers to a broad population of malignant cells characterized by the expression of ligands that trigger the cytotoxic activity of high-affinity Natural Killer (haNK) cells. haNK cells are a proprietary, irradiated NK-92 cell line engineered by ImmunityBio to express the high-affinity V158 variant of the CD16 (FcγRIIIa) receptor, which significantly enhances their ability to perform antibody-dependent cellular cytotoxicity (ADCC) when combined with therapeutic antibodies [1][3]. Beyond CD16, these cells utilize endogenous activating receptors like NKG2D and Natural Cytotoxicity Receptors (NCRs) to identify stress-induced ligands such as MICA, MICB, and ULBPs, which are frequently upregulated on the surface of various solid and hematological tumors [2][4]. This multi-receptor recognition strategy allows haNK cells to target a wide array of cancers while potentially overcoming common tumor escape mechanisms like MHC class I downregulation. In clinical settings, haNK cells are often administered alongside IL-15 superagonists (e.g., N-803) to promote their activation and persistence within the tumor microenvironment [1][5]. This target entry is considered 'incorrect' as a single molecular entity because it describes a complex interaction between a therapeutic cell line and a heterogeneous set of tumor-associated ligands rather than a specific protein or receptor [3].

Other names

haNK cell ligandsTumor-associated NK cell targetsNKG2D ligandsNatural cytotoxicity receptor ligandsCD16-mediated ADCC targets

haNK cells recognize and bind to tumor-associated ligands via a combination of an engineered high-affinity CD16 (V158) receptor and endogenous activating receptors such as NKG2D and Natural Cytotoxicity Receptors (NKp30, NKp44, NKp46). This binding triggers the release of cytotoxic granules containing perforin and granzymes, leading to the direct lysis of the target tumor cell. When used with monoclonal antibodies, the CD16 receptor facilitates enhanced antibody-dependent cellular cytotoxicity (ADCC).